Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis - PubMed (original) (raw)

Review

Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis

Rebecca Banerjee et al. Biochim Biophys Acta. 2009 Jul.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative movement disorder with unknown etiology. It is marked by widespread neurodegeneration in the brain with profound loss of A9 midbrain dopaminergic neurons in substantia nigra pars compacta. Several theories of biochemical abnormalities have been linked to pathogenesis of PD of which mitochondrial dysfunction due to an impairment of mitochondrial complex I and subsequent oxidative stress seems to take the center stage in experimental models of PD and in postmortem tissues of sporadic forms of illness. Recent identification of specific gene mutations and their influence on mitochondrial functions has further reinforced the relevance of mitochondrial abnormalities in disease pathogenesis. In both sporadic and familial forms of PD abnormal mitochondrial paradigms associated with disease include impaired functioning of the mitochondrial electron transport chain, aging associated damage to mitochondrial DNA, impaired calcium buffering, and anomalies in mitochondrial morphology and dynamics. Here we provide an overview of specific mitochondrial functions affected in sporadic and familial PD that play a role in disease pathogenesis. We propose to utilize these gained insights to further streamline and focus the research to better understand mitochondria's role in disease development and exploit potential mitochondrial targets for therapeutic interventions in PD pathogenesis.

PubMed Disclaimer

Cited by

Antioxidant-Rich Fraction of Urtica dioica Mediated Rescue of Striatal Mito-Oxidative Damage in MPTP-Induced Behavioral, Cellular, and Neurochemical Alterations in Rats.
Bisht R, Joshi BC, Kalia AN, Prakash A. Bisht R, et al. Mol Neurobiol. 2017 Sep;54(7):5632-5645. doi: 10.1007/s12035-016-0084-z. Epub 2016 Sep 13. Mol Neurobiol. 2017. PMID: 27624385
A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.
Tabrez S, Jabir NR, Shakil S, Greig NH, Alam Q, Abuzenadah AM, Damanhouri GA, Kamal MA. Tabrez S, et al. CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):395-409. doi: 10.2174/187152712800792785. CNS Neurol Disord Drug Targets. 2012. PMID: 22483313 Free PMC article. Review.
Neurotransmitter CART as a New Therapeutic Candidate for Parkinson's Disease.
Mao P, Meshul CK, Thuillier P, Reddy PH. Mao P, et al. Pharmaceuticals (Basel). 2013;6(1):108-23. doi: 10.3390/ph6010108. Pharmaceuticals (Basel). 2013. PMID: 23543038 Free PMC article.
From Brain to Muscle: The Role of Muscle Tissue in Neurodegenerative Disorders.
Duranti E, Villa C. Duranti E, et al. Biology (Basel). 2024 Sep 12;13(9):719. doi: 10.3390/biology13090719. Biology (Basel). 2024. PMID: 39336146 Free PMC article. Review.
Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson's Disease.
Ahuja M, Kaidery NA, Dutta D, Attucks OC, Kazakov EH, Gazaryan I, Matsumoto M, Igarashi K, Sharma SM, Thomas B. Ahuja M, et al. Antioxidants (Basel). 2022 Sep 9;11(9):1780. doi: 10.3390/antiox11091780. Antioxidants (Basel). 2022. PMID: 36139853 Free PMC article. Review.

References

1. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495–505. - PubMed
1. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55:259–272. - PubMed
1. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med. 1998;339:1044–1053. - PubMed
1. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med. 1998;339:1130–1143. - PubMed
1. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116:1744–1754. - PMC - PubMed

Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis - PubMed (original) (raw)